Wimberger et al., in their investigation, analysed the incidence and molecular phenotypes of EMT-like circulating tumour cells (CTCs) in the blood samples of ovarian cancer patients and monitored their responses to platinum-based chemotherapy, observing a selective enrichment of EMT-positive CTCs accompanied by the “de novo” emergence of dual PI3Kα- and Twist-positive CTCs, which may explain the therapy resistance [65]. This evidence concerns the gene TWIST1 and ovarian carcinoma.